NASDAQ:BridgeBio Pharma, Inc.

График котировок BridgeBio Pharma, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 435.81
P/BV 16.41
EV/EBITDA -19.23
Цена ао 64.28

Основные владельцы

Institutions Объем Доля, %
AIG Asset Management (U.S), LLC 5576380 4.54
Aisling Capital Management LP 3989412 3.25
Kohlberg Kravis Roberts & Co LP 34510971 28.13
SC US (TTGP), LTD. 2544738 2.08
BlackRock Fund Advisors 8099277 6.6
Perceptive Advisors LLC 6706268 5.46
Viking Global Investors LP 26620991 21.69
Cormorant Asset Management, LLC 2265762 1.85
Nicholas Investment Partners 24745 0.02
Pacific Life Fund Advisors LLC (PLFA) 159277 0.13
Fernwood Investment Management, LLC 143835 0.12
CT Mason 73425 0.06
Janus Capital Management LLC 1840285 1.5
Defiance ETFs, LLC 4435 0
Bayview Asset Management Co., Ltd. 35200 0.03
Ohio National Investments Inc 73494 0.06
Baillie Gifford Investment Management (Europe) Limited 23314 0.02
Northern Trust Investments Inc 1346837 1.1
Hillhouse Capital Advisors, Ltd. 4711604 3.84
Rockefeller & Co. LLC 117235 0.1
WCM Investment Management, LLC 6378 0.01
UBS Asset Management (Americas) Inc 32157 0.03
Kohlberg Kravis Roberts & Co LP 34510971 28.12
Donoghue Forlines LLC 24712 0.02
BAMCO Inc 25876 0.02
AMG Funds LLC 179505 0.15
American Century Investment Management, Inc 657864 0.54
Nicholas Investment Partners LP 32979 0.03
SSGA Funds Management Inc 2900278 2.36

Содержится в ETF

ETF Доля, % Доходность за год, %
Defiance Nasdaq Junior Biotechnology ETF 3.09

Похожие компании

Описание BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; and collaboration with Salk Institute for Biological Studies. The company was founded in 2015 and is headquartered in Palo Alto, California.